Article
An optimised patient-derived explant platform for breast cancer reflects clinical responses to chemotherapy and antibody-directed therapy
4 Jun 2024
Abstract excerpt
Breast Cancer is the most common cancer among women globally. Despite significant improvements in overall survival, many tumours are refractory to therapy and so novel approaches are required to improve patient outcomes. We have evaluated patient-derived explants (PDEs) as a novel preclinical platform for breast cancer (BC) and implemented cutting-edge digital pathology and multi-immunofluorescent approaches for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
